IRVINE, Calif., June 10 /PRNewswire-FirstCall/ -- Endologix, Inc.
(Nasdaq: ELGX), developer of minimally invasive treatments for
aortic disorders, announced today that it has received U.S. Food
and Drug Administration (FDA) approval for its expanded offering of
Powerlink® stent graft products. The approval covers 31 new sizes
of Powerlink® main body bifurcated, proximal extension, and limb
extension stent grafts that increase the system's addressable
patient population by 5% to 10%. The new products will be launched
in a limited market release at the 2010 Annual Meeting of the
Society for Vascular Surgery, June 10-13,
2010, at the Hynes Convention Center in Boston, MA. The Company expects to launch the
new product line extensions in a full market release during the
fourth quarter of 2010.
John McDermott, President and
Chief Executive Officer said, "The approval of our expanded
Powerlink® product line offering is a significant achievement for
Endologix as we continue to drive market adoption of our innovative
anatomical fixation technology. The broadened family of devices
will allow physicians to use our products to treat a wider group of
patients with abdominal aortic aneurysm, including those with short
common iliac arteries. In addition, the breadth of new bifurcated
devices and proximal extensions will enable physicians to tailor
the endovascular repair to each patient's unique anatomical
requirements. All of these new sizes are designed for seamless
integration with our existing products and will be delivered with
the IntuiTrak® Endovascular System. We look forward to introducing
our expanded Powerlink® product line to the medical community at
the SVS Annual Meeting and further drive broader adoption in the
fourth quarter of this year."
About Endologix, Inc.
Endologix, Inc. develops and manufactures minimally invasive
treatments for aortic disorders. The Company's flagship product is
the Powerlink® System, which is an endovascular stent graft for the
treatment of abdominal aortic aneurysms (AAA). AAA is a weakening
of the wall of the aorta, the largest artery in the body, resulting
in a balloon-like enlargement. Once AAA develops, it continues to
enlarge and, if left untreated, becomes increasingly susceptible to
rupture. The overall patient mortality rate for ruptured AAA is
approximately 75%, making it a leading cause of death in the U.S.
Additional information can be found on Endologix's Web site at
www.endologix.com.
Forward-Looking Statements
Except for historical information contained herein, this news
release contains forward-looking statements, the accuracy of which
are necessarily subject to risks and uncertainties, all of which
are difficult or impossible to predict accurately and many of which
are beyond the control of Endologix. Many factors may cause actual
results to differ materially from anticipated results, including
the success of sales efforts for the Powerlink System and related
new products, product research and development efforts, and other
economic, business, competitive and regulatory factors. The Company
undertakes no obligation to update its forward looking statements.
Please refer to the Company's Annual Report on Form 10-K for the
year ended December 31, 2009, and the
Company's other filings with the Securities and Exchange
Commission, for more detailed information regarding these risks and
other factors that may cause actual results to differ materially
from those expressed or implied.
COMPANY CONTACT:
|
INVESTOR CONTACTS:
|
|
Endologix, Inc.
|
The Ruth Group
|
|
John McDermott, CEO
|
Nick Laudico (646) 536-7030
|
|
(949) 595-7200
|
Zack Kubow (646) 536-7020
|
|
www.endologix.com
|
|
|
|
SOURCE Endologix, Inc.